Medical care disruptions during the first six months of the COVID-19 pandemic: the experience of older breast cancer survivors
Authors:
- 13 September 2021
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 190 (2) , 287-293
Abstract
Purpose Older cancer survivors required medical care during the COVID-19 pandemic, but there are limited data on medical care in this age group. Methods We evaluated care disruptions in a longitudinal cohort of non-metastatic breast cancer survivors aged 60–98 from five US regions (n = 321). Survivors completed a web-based or telephone survey from May 27, 2020 to September 11, 2020. Care disruptions included interruptions in seeing or speaking to doctors, receiving medical treatment or supportive therapies, or filling prescriptions since the pandemic began. Logistic regression models evaluated associations between care disruptions and education, medical, psychosocial, and COVID-19-related factors. Multivariate models included age, county COVID-19 death rates, comorbidity, and post-diagnosis time. Results There was a high response rate (n = 262, 81.6%). Survivors were 32.2 months post-diagnosis (SD 17.5, range 4–73). Nearly half (48%) reported a medical disruption. The unadjusted odds of care disruptions were higher with each year of education (OR 1.22, 95% CI 1.08–1.37, p = < 0.001) and increased depression by CES-D score (OR 1.04, CI 1.003–1.08, p = 0.033) while increased tangible support decreased the odds of disruptions (OR 0.99, 95% CI 0.97–0.99, p = 0.012). There was a trend between disruptions and comorbidities (unadjusted OR 1.13 per comorbidity, 95% CI 0.99–1.29, p = 0.07). Adjusting for covariates, higher education years (OR1.23, 95% CI 1.09–1.39, p = 0.001) and tangible social support (OR 0.98 95% CI 0.97–1.00, p = 0.006) remained significantly associated with having care disruptions. Conclusion Older breast cancer survivors reported high rates of medical care disruptions during the COVID-19 pandemic and psychosocial factors were associated with care disruptions. Clinicaltrials.gov Identifier NCT03451383Keywords
Funding Information
- National Cancer Institute (R01CA129769, R01CA172119, K01CA212056, R01CA237535, K08CA241337, R35CA197289, R01AG068193, P30CA008748)
- National Institutes of Health (P30CA51008, K12HD001441)
- National Institute on Aging (K01AG065485, P30AG10133, P30AG10133, P30AG028716, R01AG19771, R01LM01136, R01AG19771, R01LM01136)
- Norman Cousins Center for Psychoneuroimmunology
- American Cancer Society (128660-RSG-15-187-01-PCSM, RSG-17-023-01-CPPB)
This publication has 22 references indexed in Scilit:
- A War on Two Fronts: Cancer Care in the Time of COVID-19Annals of Internal Medicine, 2020
- Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer StudyJournal of Clinical Oncology, 2018
- The factor structure of the Medical Outcomes Study–Social Support Survey: A comparison of different models in a sample of recently diagnosed cancer patientsJournal of Psychosomatic Research, 2018
- Reliability and Validity of the Center for Epidemiologic Studies Depression Scale in a Population-Based Cohort of Middle-Aged U.S. AdultsJournal of Nursing Measurement, 2017
- Social networks, social support, and burden in relationships, and mortality after breast cancer diagnosis in the Life After Breast Cancer Epidemiology (LACE) StudyBreast Cancer Research and Treatment, 2012
- The STAI-Y trait scale: psychometric properties and normative data from a large population-based study of elderly peopleInternational Psychogeriatrics, 2012
- Low Health Literacy and Health Outcomes: An Updated Systematic ReviewAnnals of Internal Medicine, 2011
- Do stress-related psychosocial factors contribute to cancer incidence and survival?Nature Clinical Practice Oncology, 2008
- Social networks and health-related quality of life in breast cancer survivorsJournal of Psychosomatic Research, 2002
- The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.Journal of Clinical Oncology, 1993